The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Jean-François Toussaint, Sanofi's global head of vaccines R&D, speaking at a conference at the company's site in Lyon last ...

Paris: Sanofi has received the US Food and Drug Administration (USFDA) fast-track designation for its mRNA vaccine candidate ...

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...

As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety of its novel mRNA vaccine in preventing chlamydia.

Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or ...

The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.

Visby Medical’s at-home diagnostic, which can be purchased without a prescription, tests for chlamydia, gonorrhea and ...

Sanofi will commence a Phase I/II trial with its vaccine candidate in the next few days to start generating immunogenicity ...

PARIS, France I March 26, 2025 I The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention ...